Population Pharmacokinetic Analysis of Datopotamab Deruxtecan (Dato-DXd), a TROP2-Directed Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors
Background
Datopotamab deruxtecan (Dato-DXd) is a trophoblast cell surface antigen 2 (TROP2) -directed antibody-drug conjugate (ADC) developed for advanced or metastatic solid tumors, including certain types of breast cancer and non-small cell lung cancer.
About the publication
This study introduces the first population PK model for Dato-DXd, which semi-mechanistically links the pharmacokinetics of the ADC to its potent payload, DXd. The results support the rationale for weight-based dosing and validate the key clinical pharmacology label claim for Dato-DXd. The knowledge gained from this work will inform the dosing strategies for future Dato-DXd clinical studies.
This publication is a collaboration with Daiichi Sankyo and AstraZeneca. Medical writing support by Christina Pentafragka.
